Choosing a course is one of the most important decisions you'll ever make! View our courses and see what our students and lecturers have to say about the courses you are interested in at the links below.
Each year more than 4,000 choose NUI Galway as their University of choice. Find out what life at NUI Galway is all about here.
About NUI Galway
About NUI Galway
Since 1845, NUI Galway has been sharing the highest quality teaching and research with Ireland and the world. Find out what makes our University so special – from our distinguished history to the latest news and campus developments.
Colleges & Schools
Colleges & Schools
NUI Galway has earned international recognition as a research-led university with a commitment to top quality teaching across a range of key areas of expertise.
- Research & Innovation
- Business & Industry
- Alumni, Friends & Supporters
At NUI Galway, we believe that the best learning takes place when you apply what you learn in a real world context. That's why many of our courses include work placements or community projects.
January CÚRAM Welcomes Almost €5 Million in Disruptive Technologies Innovation Funding
CÚRAM Welcomes Almost €5 Million in Disruptive Technologies Innovation Funding
CÚRAM, the Science Foundation Ireland Centre for Research in Medical Devices based at NUI Galway will be involved in three key industry projects worth almost €5 million (€4.8 million) following the recent announcement of the Government’s Disruptive Technologies Innovation Fund. CÚRAM teams, in collaboration with industry partners, will be driving disruptive innovation on the key areas of medtech and connected health.
Professor Abhay Pandit, Scientific Director at CÚRAM in NUI Galway, said: “This funding of €4.8 million to CÚRAM research labs is a strong recognition of our pivotal role in the development of the next generation of medical devices and implants that target chronic illnesses. This funding is also a reflection of the close collaborative relationship we have with key industry partners with whom we will continue to work closely with on the development of these disruptive technology projects.”
Partnered with industry, the AURIGEN project will see €5.9 million being invested in a solution for persistent Atrial fibrillation of the heart. Atrial fibrillation (AF) is the most common heart rhythm disturbance in the US and Europe, significantly affecting the lives of those afflicted, causing symptoms that range from palpitations to fatigue, weakness and activity intolerance, and substantially increasing the risks of stroke, congestive heart failure, dementia and death. The consortium of AuriGen Medical (a BioInnovate Ireland spin out based at NUI Galway), the Translational Medical Device (TMD) Lab at NUI Galway and Tyndall, UCC have unique experience, expertise and proprietary technologies, which place this group in an unprecedented position to deliver a uniquely effective therapy capable of addressing both the stroke and arrhythmia risk associated with Atrial fibrillation.
The second project also sees the TMD-Lab partnering on the SMART CARDIO research project with AtriAN Medical who are also based at NUI Galway. The team will seek to develop and optimise ablation technologies for the minimally invasive treatment of particular cardiac disorders.
Dr Martin O’Halloran, Director of the TMD-Lab at NUI Galway, said: “These exciting research projects with a combined value to the TMD-Lab of almost €2 million are further evidence of NUI Galway establishing itself as a world-leader in ablation medical technology. The funding will bring an additional 10 senior post-doctoral ablation engineers to Galway, and in collaboration with our industry partners, will drive significant employment in the sector. The research will draw on expertise from both Engineering (Dr Adnan Elahi) and Medicine (Dr Atif Shahzad and Dr Leo Quinlan) from NUI Galway to deliver these disruptive technologies.”
The third project, ARDENT II will create a new therapy for patients suffering from rhinitis, an inflammatory disease which presents as nasal congestion, rhinorrhoea, sneezing and nasal itching. Congestion and rhinorrhoea are the two most impactful symptoms on a patient’s quality of life, which are usually present lifelong. Affecting tens of millions of patients worldwide, an effective treatment does not exist for moderate or severe suffers, creating a multi-billion-euro opportunity for disruptive technologies. A consortium of Neurent Medical Ltd (a BioInnovate Ireland spin out) and the Biggs lab at CÚRAM will benefit from the €2.8 million in Disruptive Technologies Innovation Funding which will be invested in the development of a new medical device technology, to address this inflammatory nasal condition through an innovative neuromodulation approach.
Dr Manus Biggs from CÚRAM at NUI Galway, said: “We are excited to work with Neurent Medical on the development of a novel approach to a significant global medical challenge. The commitment of the Irish government to the development of forward thinking disruptive technologies has the potential to place Ireland at the forefront of biomedical engineering research and development.”
The Government’s Disruptive Technologies Innovation Fund, setup as part of the Project Ireland 2040 capital investment plan, aims to provide finance to projects that tackle national and global challenges in a way that will create and secure jobs into the future.